A phase IIa trial of TRIV-509
Latest Information Update: 27 May 2025
At a glance
- Drugs TRIV-509 (Primary)
- Indications Asthma; Atopic dermatitis
- Focus Therapeutic Use
Most Recent Events
- 21 May 2025 According to a Triveni Bio media release, the company plans to initiate this study in the second half of 2025 .
- 02 Oct 2024 According to a Triveni Bio media release, triveni plans to submit an Investigational New Drug (IND) application for its lead candidate, TRIV-509, in the first quarter of 2025.
- 01 Nov 2023 New trial record